Back to top
more

Portola Pharmaceuticals, Inc. (PTLA)

(Delayed Data from NSDQ)

$36.49 USD

36.49
645,483

+0.89 (2.50%)

Updated May 3, 2019 04:00 PM ET

After-Market: $36.46 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Portola Pharmaceuticals (PTLA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of -18.92% and -26.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Alexion (ALXN) Beats on Q1 Earnings & Sales, Lowers Guidance

by Zacks Equity Research

Alexion (ALXN) beats on earnings and sales in the first quarter of 2020 but lowers view due to the ongoing pandemic.

Company News for May 6, 2020

by Zacks Equity Research

Companies in the news are: LITE, ITW, INCY, PTLA

Implied Volatility Surging for Portola Pharmaceuticals (PTLA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Portola Pharmaceuticals (PTLA) stock based on the movements in the options market lately.

Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) third-quarter results reflect an earnings beat while revenues almost match estimates. Exparel drives year-over-year growth.

Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss

by Zacks Equity Research

Mallinckrodt (MNK) misses on sales but beats on earnings in the third quarter of 2019.

Portola Pharmaceuticals (PTLA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 35.37% and 6.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance

by Zacks Equity Research

Bausch (BHC) beats on sales and earnings in the third quarter and raises annual guidance.

Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y

by Zacks Equity Research

Endo (ENDP) reports better-than-expected results for the third quarter as Xiaflex delivers a strong performance.

WIll Allergan (AGN) Beat Estimates This Earnings Season?

by Zacks Equity Research

Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q3 as loss of exclusivity of several products hurts sales.

Guardant Health (GH) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

During Guardant Health's (GH) Q3 conference call, investors will watch out for the latest news on the colorectal cancer screening rates of its LUNAR-2 blood test.

Portola Pharmaceuticals (PTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Portola Pharmaceuticals (PTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

During Catalyst's (CPRX) third-quarter 2019 conference call, investor focus will be on the sales performance of its only marketed drug Firdapse and its label expansion studies.

Sony (SNE) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Amid a challenging business environment, strategic partnerships and state-of-the-art product launches are likely to have benefited Sony's (SNE) fiscal second-quarter 2019 financial performance.

Portola Pharmaceuticals (PTLA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 12.38% and 17.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View

by Zacks Equity Research

Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.

Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

by Zacks Equity Research

Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.

Zoetis (ZTS) Looks Good: Stock Adds 7.6% in Session

by Zacks Equity Research

Zoetis (ZTS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance

by Zacks Equity Research

Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.

Portola Pharmaceuticals (PTLA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Portola Pharmaceuticals (PTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Portola Pharmaceuticals (PTLA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 0.00% and 6.38%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Portola Pharmaceuticals (PTLA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Portola Pharmaceuticals (PTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Portola Pharmaceuticals (PTLA) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Portola Pharmaceuticals (PTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Portola Up as Large-Scale Andexxa Production Gets FDA Nod

by Zacks Equity Research

Portola Pharmaceuticals (PTLA) announces FDA approval for large-scale Generation II manufacturing process for Andexxa to support commercial launch expected this month.

Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya

by Zacks Equity Research

The CHMP postpones the review timeline of Portola's (PTLA) Ondexxya (in the EU. Shares take a hit.